US protection ending in 2026: Nervous system
As of the edition of 20 October 2026, 24 drugs have US protection that ends (or has ended) in 2026 in nervous system; 13 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
24 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Afamelanotide | Ended 2026 (exclusivity) | Marketed | Clinuvel | MC1R | 1 |
| Asenapine | Ended 2026 (patent) | Marketed | AbbVie | HTR2A | 3 |
| Brivaracetam | Ended 2026 (patent) | Marketed | UCB | SV2A | 1 |
| Darunavir | Ends 2026 (patent) | Marketed | Johnson & Johnson | 0 | |
| Dasatinib anhydrous | Ended 2026 (exclusivity) | Marketed | ABL1, BLK, FGR | 12 | |
| Deflazacort | Ended 2026 (exclusivity) | Marketed | PTC Therapeutics | NR3C1 | 0 |
| Dulaglutide | Ended 2026 (computed from the first US licence) | Marketed | Eli Lilly | GLP1R | 0 |
| Elvitegravir | Ends 2026 (patent) | Marketed | Gilead Sciences | 0 | |
| Eribulin | Ended 2026 (exclusivity) | Marketed | Eisai | TUBB, TUBB1, TUBB2A | 9 |
| Escitalopram | Ended 2026 (exclusivity) | Marketed | AbbVie | SLC6A4 | 4 |
| Eslicarbazepine acetate | Ended 2026 (patent) | Marketed | Sumitomo Pharma | SCN10A, SCN11A, SCN1A | 2 |
| Gabapentin enacarbil | Ends 2026 (patent) | Marketed | Azurity Pharmaceuticals | CACNA2D1 | 2 |
| Golodirsen | Ends 2026 (exclusivity) | Marketed | Avi Biopharma | DMD | 0 |
| Ivabradine | Ends 2026 (patent) | Marketed | Amgen | HCN4 | 3 |
| Lacosamide | Ended 2026 (exclusivity) | Marketed | UCB | SCN10A, SCN11A, SCN1A | 0 |
| Leuprolide | Ended 2026 (exclusivity) | Marketed | GNRHR | 1 | |
| Onabotulinumtoxina | Ended 2026 (orphan exclusivity) | Marketed | AbbVie | SNAP25 | 0 |
| Pasireotide | Ends 2026 (patent) | Marketed | Recordati Rare Diseases | SSTR2, SSTR3, SSTR5 | 0 |
| Peginterferon beta-1a | Ended 2026 (computed from the first US licence) | Marketed | Biogen | IFNAR1, IFNAR2 | 0 |
| Perampanel | Ended 2026 (patent) | Marketed | Angelini Pharma | GRIA1, GRIA2, GRIA3 | 4 |
| Ramucirumab | Ended 2026 (orphan exclusivity) | Marketed | Eli Lilly | KDR | 1 |
| Sitagliptin | Ends 2026 (patent) | Marketed | Merck & Co. | DPP4 | 1 |
| Tiopronin | Ended 2026 (exclusivity) | Marketed | Mission Pharmacal | 0 | |
| Tolvaptan | Ended 2026 (patent) | Marketed | Otsuka | AVPR2 | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2026 in nervous system
In the product13 of these 24 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.